A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2385-2394

  Cheng, Sonia ^a   Serra, Stefano ^a   Mercado, Moises ^b   Ezzat, Shereen ^a   Asa, Sylvia L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; CYTOKERATIN 19; ESTROGEN RECEPTOR BETA; GALECTIN 3; HECTOR BATTIFORA MESOTHELIAL ANTIGEN 1; PROTEIN P27; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER INVASION; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEOMICS; RISK ASSESSMENT; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR ABLATION; WILD TYPE;

CARCINOMA, PAPILLARY; CYCLIN D1; DNA MUTATIONAL ANALYSIS; ESTROGEN RECEPTOR BETA; FEMALE; GALECTIN 3; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; MALE; MUTATION; PROGNOSIS; PROTEOME; PROTEOMICS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79954579610     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2837     Document Type: Article

References (32)

1. De Lellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and genetics of tumours of endocrine organs. World Health Organization. Lyon, France: IARC Press, 2004.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29. (Pubitemid 38443417)
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
4. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-40. (Pubitemid 39336372)
5. Elsheikh TM, Asa SL, Chan JK, De Lellis RA, Heffess CS, LiVolsi VA, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 2008;130:736-44.
6. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9. (Pubitemid 41759286)
7. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
8. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 2007;67:5461-70. (Pubitemid 46997287)
9. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;14:338-42. (Pubitemid 32298919)
10. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, De La Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005;18:48-57. (Pubitemid 40128094)
11. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999;141:443-57.
12. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001;98:15044-9. (Pubitemid 34013966)
13. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression of cyclin D1 and under expression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002;87:1814-8. (Pubitemid 34615274)
14. Khoo ML, Ezzat S, Freeman JL, Asa SL. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002;87:1810-3. (Pubitemid 34615273)
15. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C. Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biol 2005;26:50-6. (Pubitemid 40529298)
16. Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA, et al. Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol 1997;8:21-8. (Pubitemid 127499988)
17. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007;26:2747-58. (Pubitemid 46663832)
18. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, et al. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 2005;90:5270-8. (Pubitemid 41262285)
19. Liu W, Asa SL, Ezzat S. 1alpha, 25-dihydroxyvitamin D3 targets PTENdependent fibronectin expression to restore thyroid cancer cell adhesiveness. Mol Endocrinol 2005;19:2349-57. (Pubitemid 41252827)
20. Ryu S, Jimi S, Eura Y, Kato T, Takebayashi S. Retention of intracellular fibronectin expression in primary and metastatic thyroid carcinoma: an immunohistochemical study. Cancer Lett 1998;133:215-22. (Pubitemid 29069047)
21. Motti ML, Califano D, Baldassarre G, Celetti A, Merolla F, Forzati F, et al. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis 2005;26:1021-34. (Pubitemid 41214295)
22. Liu W, Cheng S, Asa SL, Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res 2008;68:8104-12.
23. Cheng S, Liu W, Mercado M, Ezzat S, Asa SL. Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. Endocr Relat Cancer 2009;16:455-66.
24. Kroll TG. Molecular rearrangements and morphology in thyroid cancer. Am J Pathol 2002;160:1941-4. (Pubitemid 34663385)
25. User's Guide. Aperio Technologies I. Revision A; 2008.
26. Mete O, Rotstein L, Asa SL. Controversies in thyroid pathology: thyroid capsule invasion and extrathyroidal extension. Ann Surg Oncol 2001;17:386-91.
27. Asa SL. My approach to oncocytic tumours of the thyroid. J Clin Pathol 2004;57:225-32. (Pubitemid 38338828)
28. Fischer S, Asa SL. Application of immunohistochemistry to thyroid neoplasms. Arch Pathol Lab Med 2008;132:359-72. (Pubitemid 351328811)
29. Takeichi N. Relation between estrogen receptor and malignancy of thyroid cancer. Jpn J Cancer Res 1991;82:19-22.
30. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995;76:1643-54.
31. Manole D, Schildknecht B, Gosnell B, Adams E, Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J Clin Endocrinol Metab 2001;86:1072-7. (Pubitemid 32322984)
32. McClellan DR, Francis GL. Thyroid cancer in children, pregnant women, and patients with Graves' disease. Endocrinol Metab Clin North Am 1996;25:27-48. (Pubitemid 26082761)